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Abstract
Background: Genome editing technologies developed around the CRISPR-Cas9 nuclease system have facilitated
the investigation of a broad range of biological questions. These nucleases also hold tremendous promise for
treating a variety of genetic disorders. In the context of their therapeutic application, it is important to identify the
spectrum of genomic sequences that are cleaved by a candidate nuclease when programmed with a particular
guide RNA, as well as the cleavage efficiency of these sites. Powerful new experimental approaches, such as
GUIDE-seq, facilitate the sensitive, unbiased genome-wide detection of nuclease cleavage sites within the genome.
Flexible bioinformatics analysis tools for processing GUIDE-seq data are needed.
Results: Here, we describe an open source, open development software suite, GUIDEseq, for GUIDE-seq data
analysis and annotation as a Bioconductor package in R. The GUIDEseq package provides a flexible platform with
more than 60 adjustable parameters for the analysis of datasets associated with custom nuclease applications.
These parameters allow data analysis to be tailored to different nuclease platforms with different length and
complexity in their guide and PAM recognition sequences or their DNA cleavage position. They also enable users
to customize sequence aggregation criteria, and vary peak calling thresholds that can influence the number of
potential off-target sites recovered. GUIDEseq also annotates potential off-target sites that overlap with genes based
on genome annotation information, as these may be the most important off-target sites for further characterization.
In addition, GUIDEseq enables the comparison and visualization of off-target site overlap between different datasets
for a rapid comparison of different nuclease configurations or experimental conditions. For each identified off-
target, the GUIDEseq package outputs mapped GUIDE-Seq read count as well as cleavage score from a user
specified off-target cleavage score prediction algorithm permitting the identification of genomic sequences with
unexpected cleavage activity.
Conclusion: The GUIDEseq package enables analysis of GUIDE-data from various nuclease platforms for any species
with a defined genomic sequence. This software package has been used successfully to analyze several GUIDE-seq
datasets. The software, source code and documentation are freely available at http://www.bioconductor.org/
packages/release/bioc/html/GUIDEseq.html.
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Background
Type II CRISPR/Cas adaptive defense systems employ a
single, large multi-subunit endonuclease (Cas9) and a pair
of RNAs that as a complex mediate sequence-specific
targeted cleavage of foreign DNA [1]. This system has been
repurposed into a powerful two-component system (Cas9
& single guide RNA (sgRNA)) for targeted genome editing
[2, 3]. The Cas9-sgRNA complex is straightforward to tar-
get to a desired DNA sequence because sequence-specific
recognition is achieved primarily through Watson-Crick
pairing of the associated sgRNA. The short Protospacer Ad-
jacent Motif (PAM), which is recognized by the Cas9 pro-
tein, is the chief constraint on the target site design density
within a genome, although the activity of the Cas9-sgRNA
complex is influenced by both target sequence composition
and biological features [4, 5]. Because of its simplicity and
efficacy, this technology is revolutionizing experimental
approaches in the biological sciences and holds tremen-
dous promise for therapeutic applications [6, 7].
Cleavage of unintended sequences within the genome
is one concern associated with the therapeutic applica-
tion of CRISPR-Cas9 nucleases [8]. S. pyogenes Cas9
(SpCas9)-based nucleases can cleave an imperfect het-
eroduplex formed between the guide sequence and a
DNA sequence containing a functional PAM [9–16],
where the number, position and type of base mismatches
impact its level of activity [11, 12, 16]. Deep sequencing
analysis of potential off-target sites [11–14, 17, 18] from
populations of SpCas9-sgRNA treated cells revealed that
the majority of mismatched sequences are not appreciably
cleaved, but that a subset of these “off-target” sites are func-
tional [11–14, 17, 18], where up to six mismatches [19, 20]
or a single base bulge [15, 19, 21] between the guide and
genomic sequence can be tolerated under some conditions.
To address this inherent promiscuity, SpCas9 variants with
improved precision have been developed [13, 16, 22–28]
that can dramatically reduce off-target activity. In addition,
other Cas9 [21, 29, 30] and Cpf1 [31, 32] orthologs have
precision that is comparable or superior to SpCas9. Des-
pite these advances nuclease precision is still target site
dependent. Consequently, for therapeutic applications an
unbiased assessment of genome-wide nuclease activity is
warranted, since DNA breaks at unintended sites could
alter gene expression or gene function through direct mu-
tagenesis or genomic rearrangements [33–37].
A new suite of genome-wide off-target detection methods
have been described that can identify genomic sites with
moderate to low cleavage activity within a population of
nuclease-treated cells [19–21, 33, 38]. One of the most sen-
sitive and straightforward methods to employ is GUIDE-
seq [19]. This method relies on NHEJ-mediated DNA
repair to capture co-introduced blunt-ended double
stranded oligonucleotides (dsODNs) at nuclease-induced
breakpoints within the genome, thereby tagging these loci
for selective amplification and subsequent deep sequencing.
GUIDE-seq is quite sensitive, as off-target sites with >0.1%
indel frequency can be detected [19]. Importantly, the fre-
quency of dsODN insertion appears to be correlated with
the frequency of Cas9-induced lesions at each site [19].
GUIDE-seq has been used successfully to evaluate the pre-
cision of SpCas9 [19, 39], SpCas9 variants [19, 25, 27, 28]
and two Cpf1 orthologs [32].
While the GUIDE-seq method is straightforward to
employ, its data processing is complex [19]. GUIDE-seq
combines two complementary libraries to define the loca-
tion of dsODN insertions within the genome. In addition, it
uses a non-standard indexing method with a unique mo-
lecular index to filter out duplicate sequences that arise
during the PCR amplification steps. Currently, only a single
bioinformatics application has been released to the com-
munity to support the analysis of GUIDE-seq data [40].
Although the existing tool has successfully been used for
analyzing GUIDEseq data from SpCas9 [19], the released
version is not ideal for nucleases that employ guides of
longer length or more complex PAM recognition patterns,
where control over the number of mismatches allowed
within each element for off-target identification is poten-
tially valuable [21, 29, 41, 42]. In addition, the existing tool
does not support the comparative analysis of GUIDE-seq
studies across related guides or Cas9 variants, which can be
useful when evaluating guide/Cas9 variant combinations
with the most favorable precision.
In the course of establishing GUIDE-seq in our
laboratories [25, 39], we developed an extensively docu-
mented Bioconductor package GUIDEseq that provides a
flexible tool for the analysis of GUIDE-seq datasets
interrogating nuclease specificity. GUIDEseq utilizes a
rich parameter set that permits adaptation to the charac-
teristics of alternate nuclease platforms (e.g. variants or
orthologs of Cas9 [21, 29, 41] or Cpf1 [42]), such as
different length and complexity in their guide and PAM
recognition sequences or their DNA cleavage position.
Importantly, these parameters facilitate flexible filtering
criteria for peak calling and for off-target site assign-
ment, which can be critical for the capture of potential
off-target sites depending on the type of nuclease system
that is employed. Our software can also annotate off-
target sites to indicate whether they fall within a critical
region of the genome, such as the exon of a gene. In
addition, our algorithm allows multiple GUIDE-seq
datasets from different experiments to be compared to
identify cleaved genomic sites that are overlapping or
unique for a particular guide RNA/nuclease within a group.
Implementation
Implementation platform
GUIDEseq implements a common workflow for GUIDE-
seq data analysis and annotation as a Bioconductor
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package in R [43, 44]. Developing GUIDEseq as a Biocon-
ductor package allows us to leverage a large number of
existing genome analysis [45–49] and visualization [50]
tools supported within the Bioconductor project. In
addition, the rich annotation data for assembled genomes
that are available can be used to associate genomic
features with identified off-target sites. Bioconductor is an
open source and open development software project
(http://www.bioconductor.org), which is updated twice a
year, where the current release (Bioconductor 3.5) consists
of more than two thousand software and annotation pack-
ages. These include many species-specific BSgenome
packages for accessing different reference genomic se-
quences, as well as OrgDb and TxDb annotation packages
for accessing annotation information for a variety of
species. In addition, utilities are provided within the
Bioconductor project to forge customized BSgenome and
TxDb packages. These resources provide end-users with a
flexible, stable and up-to-date platform for implementing
data analysis for a variety of different systems or for
customizing the output for a specific system of interest.
Read preprocessing, mapping, filtering, peak calling and
off-target identification
In the GUIDE-seq protocol [19], two different paired-end
sequencing libraries are generated from the genomic
DNA from each nuclease treatment group. These libraries
(forward and reverse) differ in the primers (complemen-
tary to one of the two strands of the GUIDE-seq oligonu-
cleotides) that are utilized to amplify genomic regions that
are “tagged” by GUIDE-seq oligonucleotide integration.
During the construction of these libraries a UMI is incor-
porated during the distal adaptor ligation, which identifies
unique sequencing reads within the paired-end sequen-
cing run. Unique sequencing reads are then aggregated
within a defined window and peaks that are potential off-
target sites are identified using data from both libraries
based on end-user supplied filtering criteria.
Within our GUIDEseq package, we have integrated
powerful sequence analysis algorithms and functional-
ities from other Bioconductor packages for many stages
of the GUIDE-seq data processing. In addition, our
GUIDEseq package provides more than 60 adjustable
parameters to describe the nuclease sequence preference
and allow customized data analysis. For simplicity, the
majority of nuclease-specific parameters are preset to
correspond to the standard SpCas9 nuclease system, but
they can be modified to conform to the characteristics
of alternate nuclease platforms (e.g. gRNA sequence and
length, and PAM sequence preference and position rela-
tive to protospacer). The data analysis parameters permit
detailed adjustment of the read filtering criteria, peak-
calling parameters (read aggregation window size and
coverage threshold), and peak merging criteria. Importantly,
extensive documentation is included describing the param-
eters for customization of this package.
An overview of the GUIDEseq analysis workflow is
given in Fig. 1. Species-specific genomic sequence and
annotations are loaded using BSgenome, TxDb and
orgAnn packages. Preprocessing scripts to extract the
UMI sequence, bin sequencing reads associated with
different libraries based on the index sequences, remove
the constant dsODN sequences, and map the resulting
sequencing reads to a desired genome assembly are avail-
able at http://mccb.umassmed.edu/GUIDE-seq/. Prepro-
cessing steps are described in detail in the Supplementary
Methods section [see Additional file 1]. Within the
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Fig. 1 Overview of GUIDEseq Analysis Workflow. Schematic
representation of the GUIDEseq analysis pipeline. Input files
required for preprocessing and GUIDEseq package are represented
by annotated color arrows. First, Preprocessing Utilities are supplied to
demultiplex the Illumina FASTQ files based on the index information and
map the sequence files to the reference genome. This generates the
experimental input files (BAM and UMI files) needed for the GUIDEseq
pipeline, which are supplemented with information on the guide RNA
(gRNA) and PAM element by the end-user. Key steps carried out by the
algorithms within the GUIDEseq pipeline are indicated under the different
headers. Details about the R-based commands and variables used within
GUIDEseq are presented in the Use Cases within the main text, and are
described in full in the Installation and Usage Section [see Additional
file 1] and in the manual pages associated with the program
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GUIDEseq package, read alignments are filtered to remove
paired reads that lack a segment of the GUIDE-seq oligo-
nucleotide sequence (reads originating from a dsODN
insertion should contain a segment of its sequence; Fig. 2).
In addition, paired reads that are too far away from each
other, or that are of insufficient length or mapping quality
are removed. Because PCR amplification leads to a biased
representation of the starting sequence population, paired
reads from the same library that share an identical genomic
location for the genomic adaptor ligation site, dsODN
insertion site, and UMI sequence are collapsed together
into a single paired read (Fig. 2). For the purposes of peak
calling at the putative nuclease cleavage site, these data are
represented as a single genomic position defined by the
GUIDE-seq dsODN insertion site with the strand corre-
sponding to Read 2 (Fig. 2). All alignment filtering criteria
have a default setting but can be easily adjusted by users.
Unique putative cleavage sites from the forward and
reverse libraries are merged and clusters of these sites on
the same strand (Watson or Crick) are aggregated over a
user-defined sliding window of a specific sequence length
(default = 20 nucleotides, Fig. 3). The height of each
strand-specific peak equals the sum of the unique putative
cleavage sites within the window, and its position is
defined by the center of the 20 base window. Peak calling
also filters out clusters with a small number of putative
cleavage sites or a high pvalue calculated from a Poisson
distribution based on the local background estimate
(default to a 5 kb window). Next, the incorporated ChIP-
peakAnno package merges neighboring peaks on the
Watson and Crick strands within a defined distance
threshold if they have the correct polarity (Crick peaks
should precede Watson peaks, Fig. 3) [46, 47]. The height
of the merged peaks equals the sum of the heights of the
individual peaks, and the location parameter captures the
positions of the merged peaks. By default, peaks that lack
a Watson/Crick pair and that are only present in one
library (forward or reverse) are filtered out [19]. If desired,
(nuclease-independent) genomic hotspots for oligonucleo-
tide integration can be removed by comparison against a
nuclease-free treatment group [19].
Identified peaks are classified as potential off-target sites
based on their sequence homology to the guide sequence
and the PAM preference of the Cas9 nuclease (target site)
that was employed. GUIDEseq provides multiple parame-
ters to adjust the threshold for the calling of potential off-
target sites within or around peaks passing the filtering
criteria to allow adaptation to the type of nuclease (PAM
preference) and guide sequence that is employed. Classifi-
cation of an off-target site is defined by a maximum num-
ber of allowed base mismatches to the guide sequence and
a separate number of allowed base mismatches to the user-
defined PAM, which is implemented using the CRISPRseek
package and integrated into the GUIDEseq suite [48, 49].
This separation of the filters for the guide and PAM se-
quences allows different emphasis to be placed on these
elements in the search for potential off-target sequences
neighboring GUIDE-seq peaks. GUIDEseq calculates an
off-target cleavage prediction score for all identified poten-
tial off-target sites using mismatch penalty scoring models
generated from an experimental dataset for SpCas9 [5, 12]
or a user supplied scoring matrix. Based on the available
genome annotation, off-target sites in potentially critical re-
gions, such as exons, are flagged. These data for all identi-
fied potential off-target sites are output in a tab-delimited
format for easy manipulation within spreadsheet or
GUIDE-seq
oligo tag
(reverse library)
Read 2
primer p5 Index
+ UMI
Read 1
primer
P7 Index Genomic sequence
Genomic adaptor
ligation site
dsODN genomic
integration site
Genomic adaptor
ligation site
dsODN genomic
integration site
GUIDE-seq
oligo tag
(forward library)
Read 1
primerp5 Index
+ UMI
Read 2
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Fig. 2 Schematic of the GUIDE-seq library features used for unique read identification. Schematic overview of the two sequencing libraries that
are generated using the GUIDE-seq method [19]. Each library (forward and reverse) has a different GUIDE-seq oligo tag fragment (red or blue) that
is a part of the resulting read 2 sequences. Paired-end reads from different libraries are aggregated based on the p5 and p7 indices. Unique reads
within each library are defined based on three identifiers: the unique molecular index (UMI) in the p5 index read, the p5 adaptor genomic ligation
site, and the GUIDE-seq dsODN integration site. Redundant reads are discarded. For the purposes of peak calling, unique paired-end reads are
condensed into single-base genomic ranges that define the position of the GUIDE-seq dsODN integration site and the genomic reference
sequence strand associated with read 2
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graphing applications. Finally, if a visual comparison of the
overlap in identified potential off-target sites between differ-
ent nucleases or treatment conditions is desired, a Venn
diagram of peak overlap in up to five different datasets can
be plotted through the integrated limma package [50].
More detailed information on the commands and instruc-
tions for running the software are included in the Installa-
tion and Usage section [see Additional file 2] and in the
associated user guide (https://bioconductor.org/packages/
release/bioc/manuals/GUIDEseq/man/GUIDEseq.pdf and
http://bioconductor.org/packages/release/bioc/vignettes/
GUIDEseq/inst/doc/GUIDEseq.pdf).
Results
Analysis of published GUIDE-seq dataset
To evaluate the performance of our GUIDEseq analysis
package, we analyzed several datasets produced in house
and successfully identified the intended target sites and
validated GUIDE-seq identified off-targets using deep se-
quencing of PCR amplicons spanning these genomic loci
from nuclease-treated cells [25]. In addition, we analyzed
a dataset generously supplied by the Joung laboratory
(HEK293 guide 4), and then compared our list of identi-
fied off-target sites with their previously published
analysis [19]. An example GUIDEseq output file for this
dataset is displayed in Additional file 3: Table S1. Each
potential off-target site is listed on a separate row ranked
based on the peak score (number of unique reads
mapped within this region). In addition to the sequence
of the potential off-target site, the output includes: the
genomic position, its DNA strand, the number of mis-
matches to the guide sequence and their position and
type, and the number of mismatches to the canonical
PAM pattern supplied by the user. When gene annota-
tion is supplied for the genome assembly, the transcript
(name and entrez-ID) in which the off-target site falls is
noted, and whether it occurs within an exon. In addition,
for SpCas9, the predicted cleavage score is listed for each
site based on the mismatch scoring model generated
from the experimental data [5], where a score of 1 indi-
cates predicted activity similar to the target sequence.
When comparing our output to the previously published
analysis from the Joung laboratory [19], the number of
potential off-target sites and unique reads associated with
each peak (their rank order) are very similar (Additional
file 4: Table S2). Both outputs are in agreement over the
top 90 peaks with only minor differences in the rank order
of peaks. The discrepancies between the peak lists are
likely due to methodological differences in the sequence
filtering, aggregation, and peak-calling criteria that are
employed. The unique contributions of our package in-
clude its easy adaptability to the analysis of GUIDE-seq
datasets from various nuclease platforms, the ability to
incorporate annotations of genomic features for identified
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Fig. 3 Unique read aggregation into peaks for the identification of potential nuclease cleavage sites. Strand-specific unique reads defined by the
GUIDE-seq dsODN integration site and the read 2 genomic reference sequence strand are aggregated over a user-defined window size (20 base
default) to define strand-specific peaks. Windows with a read number greater or equal to a user-defined threshold (default = 5) are called peaks.
In addition, the signal to noise ratio (SNratio) and a p-value are computed based on the local background window size (defaults 5 kb and Poisson
distribution), which can also be employed as filters if desired. For each integration site, the Crick peak should precede the corresponding Watson
peak based on the library construction method [19]. Consequently, this order is required to combine counts from the Watson and Crick peaks over
a user-defined window size (40 base default). This aggregate “score” is used to rank peaks. The genomic region surrounding each peak (adjustable
variables, default 20 bases on each side) is used to search for sequences with homology to the nuclease sequence preference (based on the input
guide sequence (gRNA.file) and the PAM sequence (PAM), and the allowed mismatches within each element defined by the parameters: max.mismatch,
PAM.pattern and allowed.mismatch.PAM. The GUIDE-seq data shown were generated in house for SpCas9 programmed with a sgRNA to recognize
VEGFA site 2 (TS2; protospacer underlined, PAM in red) [11], where the most common dsODN integration site falls at the expected cleavage site within
this sequence (green line, hg19)
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off-target sites and its comparative analysis and
visualization features between different GUIDE-seq
datasets, which are illustrated in the following use cases.
Use cases
To simplify the use of the GUIDEseq analysis package,
all steps have been integrated into a single workflow
function GUIDESeqAnalysis. Once the package is loaded
and all of the experiment-specific parameters are set,
one line of code (GUIDEseqAnalysis) can perform all the
analysis by calling various helper functions. Below are a
few examples illustrating how to analyze a GUIDE-seq
dataset from three commonly used nucleases, with
different PAM orientation, PAM sequence preference,
PAM length, gRNA length and reference genome.
Example 1. Analysis of SpCas9 GUIDE-seq data
Although the analysis workflow function GUIDEseqAnaly-
sis has more than 60 parameters for customized analysis,
the majority of these parameters are pre-set for analyzing
GUIDE-seq data from the most commonly used nuclease,
SpCas9. Consequently when analyzing SpCas9 data only a
small number of target-specific inputs are required from
users. Detailed description of these parameters and the in-
put files are available at http://bioconductor.org/packages/
release/bioc/manuals/GUIDEseq/man/GUIDEseq.pdf. In-
formation on these parameters can also be accessed from
the manual pages by typing help(GUIDEseqAnalysis) in an
R session. Below is an example that defines the required
parameters for analysis of SpCas9 data.
Next create and set the desired working and output
directory.
Then set the file paths for target sequence (gRNA.-
file), sequence alignment (alignment.inputfile) and UMI
input files (umi.inputfile). The following code assumes
that the input files are located in the current working
directory. The gRNA file contains the gRNA sequence
in fasta format.
Finally, call the GUIDEseqAnalysis workflow function
and save the analysis results in guideSeqResults. The
annotated potential off-target sites are output as a tab
delimited file (offTargetsInPeakRegions.xls) in the output
directory specified by the user.
By default, the predicted cleavage score is calculated
using the weight matrix and scoring algorithm from
the Zhang laboratory [12]. To use the algorithm de-
veloped by the Root Laboratory [5] set the scoring.-
method = "CFDscore". In addition, combineOfftargets
(detailed in Example 5 below) can be used to remove
off-targets common with a nuclease-free control (e.g.
cell type specific double strand break hot spots [19]).
Example 2. Analysis of NmCas9 GUIDE-seq data
Compared to SpCas9, NmCas9 has a longer gRNA (24
nucleotides), and different PAM sequence preference
(NNNNGATT) [41]. Below is an example of the parame-
ters and code needed to analyze GUIDE-seq data from
NmCas9. There are only a few additional parameters must
be set, i.e., PAM, PAM.size, PAM.pattern, allowed.mis-
match.PAM, gRNA.length and weights (to avoid using the
SpCas9 default parameters). Currently, there is no position-
specific mismatch penalty matrix available for NmCas9.
However, if desired the weight matrix from SpCas9 can be
borrowed by simply padding 4 zeros at the beginning of the
weight matrix, or an alternate weight matrix can be input
(weights). In addition, other parameters that influence the
homology search for potential off-target sites within identi-
fied peaks should be adjusted. The maximum number of
mismatches to the guide (max.mismatch) and PAM
(allowed.mismatch.PAM) can be tuned to increase/decrease
the specificity/sensitivity of the analysis. In addition, PAM.-
pattern allows the user to require a specific PAM sequence
pattern to be present for additional constraint on the recov-
ered sequences if desired. In the example below potential
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off-target sites are allowed ten mismatches within the guide
sequence (24 nucleotides in length), three mismatches
within the PAM (8 nucleotides in length), but the PAM is
required to have a G at the fifth position.
Example 3. Analysis of Cpf1 GUIDE-seq data
AsCpf1 is an RNA-guided nuclease recognizing a T-rich
PAM, TTTN, on the 5' side of the protospacer [42], unlike
SpCas9, which recognizes an NGG PAM on the 3' side of
the protospacer. Below is an example of the parameters
and code to analyze a GUIDE-seq dataset for AsCpf1. In
addition to the parameters discussed for NmCas9, there is
one more parameter to be changed, i.e., PAM.location,
which sets the PAM to the 5’ side of the protospacer.
Another advantage of our GUIDEseq package is the abil-
ity/flexibility to plug in additional annotation packages
within Bioconductor. Although we only present examples
for the analysis of human genome datasets, BSgenome-
Name can be set to analyze data from other species, such
as the Mmusculus package for mouse (BSgenome.Mmus-
culus.UCSC.mm10), the Rnorvegicus package for rat (BSge-
nome.Rnorvegicus.UCSC.rn6), the Scerevisiae package for
yeast (BSgenome.Scerevisiae.UCSC.sacCer3), the Celegans
package for C. elegans (BSgenome.Celegans.UCSC.ce11),
and the Dmelanogaster package for D. melanogaster
(BSgenome.Dmelanogaster.UCSC.dm6). For a list of
available species-specific BSgenomes, please search for
keyword “BSgenome” at https://bioconductor.org/pack-
ages/3.3/BiocViews.html#___AnnotationData. For ge-
nomes not available as Bioconductor packages, users or
the core team can create one using the utility detailed
at http://www.bioconductor.org/packages/release/bioc/
vignettes/BSgenome/inst/doc/BSgenomeForge.pdf.
Example 4. Annotate off-targets
With parameters txdb and organAnn set to an organism-
specific transcript object and gene ID mapping object, off-
target sites are annotated if they overlap with gene bodies and
if they fall within an exon. Here is an example for SpCas9
GUIDE-seq data processing that annotates identified potential
off-target sites with features from the human genome.
To annotate off-targets in other genomes, set txdb and
orgAnn accordingly. For example, set txdb to TxDb.Mmus
culus.UCSC.mm10.knownGene and orgAnno to org.M
m.eg.db for mouse, txdb to TxDb.Rnorvegicus.UCSC.rn6.
refGene and orgAnno to org.Rn.eg.db for rat, txdb to
TxDb.Dmelanogaster.UCSC.dm6.ensGene and orgAnno
to org.Dm.eg.db for D. melanogaster, and txdb to
TxDb.Celegans.UCSC.ce11.ensGene and orgAnno to org.-
Ce.eg.db for C. elegans. For a list of existing TxDb and
gene ID mapping packages search for keywords “Txdb”
and “OrgDb” at http://www.bioconductor.org/packages/
release/BiocViews.html#___AnnotationData. Please refer
to GenomicFeatures package for creation of additional
transcript packages.
Example 5. Merge off-targets from multiple experiments
to facilitate comparisons among different nuclease
configurations or variants
When evaluating novel nuclease treatment conditions
or different Cas9 variants, it is common practice to
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include off-target analysis of standard platforms as
controls. To aid in comparisons between different nu-
cleases, off-targets identified by GUIDE-seq can be
easily merged using the combineOfftargets function.
Here is the example code to merge three experiments
and generate a Venn diagram to depict the off-target
overlaps among experiments (Fig. 4).
If desired combineOfftargets can be used to remove
off-targets common among different gRNAs by setting
remove.common to TRUE. Furthermore, if a control
sample without nuclease is available, peaks present in
the control sample can be removed from the gRNA
samples by setting the control.sample.name.
Conclusions
GUIDEseq provides a flexible analysis platform for the
identification and annotation of nuclease-based off-
target cleavage sites that are tagged through the
GUIDE-seq methodology developed by the Joung
laboratory [19]. Harnessing the diverse software re-
sources and databases available within Bioconductor
[45, 46, 48, 50], GUIDEseq provides a streamlined en-
vironment for the identification of off-target sites in a
wide variety of species. In comparison to the recently
released guideseq analysis pipeline in python [40], our
package provides a rich parameter set that allows
users to easily modify the processing of GUIDE-seq
data to adapt to a variety of different types of nucle-
ases by accommodating different target sequence
characteristics, such as gRNA length, canonical PAM
sequence composition and position of the PAM rela-
tive to the protospacer. In addition, GUIDEseq allows
the definition of different filtering and peak calling
criteria, as well as different target site complementar-
ity thresholds for both the guide sequence and PAM
element for the capture of potential off-target se-
quences that are associated with GUIDE-seq peaks.
This flexibility, which is absent in the python analysis
pipeline [40], allows the differential tuning of these
features for the more liberal capture of potential off-
target sites for subsequent validation.
Furthermore, our GUIDEseq package has a number of
additional distinct features. It can output an off-target
cleavage prediction score for each site based on the
complementarity to the input target sequence using ac-
tivity models generated from a variety of experimental
datasets [5, 12]. Deviations in the off-target cleavage
rates from the predicted score may identify sites where
biological factors are impacting nuclease cleavage rates,
which could inform subsequent iterations of these activ-
ity models. Our GUIDEseq package also permits the
utilization of different annotation packages such as BSge-
nome and TxDb to define putative off-target sites that
overlap features of interest within a genome. This infor-
mation can be used to prioritize the validation of identi-
fied potential off-target sites. In addition, our package
allows a comparative analysis of nuclease precision and
visualization of identified off-target sites from different
experiments in a Venn diagram. This feature may be
particularly valuable when different nuclease treatment
conditions or nuclease platforms are being compared to
define the most promising nuclease framework to pur-
sue for future studies.
User information
A step-by-step user guide with working code snippets
for the GUIDEseq analysis package is available at http://
bioconductor.org/packages/release/bioc/vignettes/GUID
Eseq/inst/doc/GUIDEseq.pdf. Detailed parameter defin-
ition, default setting and usage are available at https://
bioconductor.org/packages/release/bioc/manuals/GUIDE
seq/man/GUIDEseq.pdf. GUIDEseq depends on R ver-
sion 3.3.0 or later.
Wild-type SpCas9 SpCas9MT3-ZFP
Split-SpCas9 dual NLS
22
4
0
28
98
1
9
Fig. 4 Venn Diagram generated using combineOfftargets to depict
the overlaps of off-target sites between three different nuclease
variants. Example of the output from the combineOfftargets function
(Example 6) comparing the overlap in GUIDE-seq identified off-
target sites for wild-type Cas9, Split-Cas9 (dual NLS) [51], and the
highly specific SpCas9MT3-ZFP [25] programmed with a sgRNA
recognizing VEGFA site 2 (TS2) [11]
Zhu et al. BMC Genomics  (2017) 18:379 Page 8 of 10
Additional files
Additional file 1: Supplemental Methods for GUIDE-seq data
preprocessing. (PDF 166 kb)
Additional file 2: Installation and Usage of GUIDEseq for novice R users.
(PDF 224 kb)
Additional file 3: Table S1. An example output of GUIDEseq analysis.
(XLSX 72 kb)
Additional file 4: Table S2. Common and unique off-targets identified
by GUIDEseq and published in Tsai 2015 [19]. (XLSX 32 kb)
Abbreviations
CRISPR: Clustered regularly interspaced short palindromic repeats; DSB: Double-
strand break; GUIDE-seq: Genome-wide unbiased identification of DSBs enabled
by sequencing; PAM: Protospacer adjacent motif
Acknowledgements
The authors would like to thank Shengdar Tsai & J. Keith Joung for sharing
sequencing data of HEK239_site4 for the comparative analysis.
Funding
This work was supported by NIH grant R01AI117839 & R01HL093766 to S.A.W.
Availability of data and materials
GUIDEseq is an open source software package under the GNU General
Public License v2.0 and has been contributed to the Bioconductor Project.
The software, source code and documentation are available for download
from http://www.bioconductor.org/packages/release/bioc/html/
GUIDEseq.html or installed from R by typing source("http://bioconductor.org/
biocLite.R") and biocLite("GUIDEseq"). The datasets analyzed in this study
were generously supplied by the Joung laboratory or were generated in
house.
Authors’ contributions
LJZ and SAW conceived and designed the computational method. LJZ, ML
and HP developed the software package. LJZ and AG analyzed the data. LJZ
and SAW wrote the paper. All authors read and approved the final
manuscript.
Competing interests
The authors have filed patent applications related to genome engineering
technologies. S.A.W. is a consultant for Editas Medicine.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Molecular, Cell and Cancer Biology, University of
Massachusetts Medical School, Worcester, MA, USA. 2Program in
Bioinformatics and Integrative Biology, University of Massachusetts Medical
School, Worcester, MA, USA. 3Department of Molecular Medicine, University
of Massachusetts Medical School, Worcester, MA, USA. 4Genentech, San
Francisco, CA, USA. 5Program in Computational Biology, Fred Hutchinson
Cancer Research Center, Seattle, WA 98109-1024, USA. 6Department of
Biochemistry and Molecular Pharmacology, University of Massachusetts
Medical School, Worcester, MA, USA.
Received: 27 March 2017 Accepted: 1 May 2017
References
1. Sontheimer EJ, Barrangou R. The bacterial origins of the CRISPR genome-
editing revolution. Hum Gene Ther. 2015;26(7):413–24.
2. Doudna JA, Charpentier E. Genome editing. The new frontier of genome
engineering with CRISPR-Cas9. Science (New York, NY). 2014;346(6213):
1258096.
3. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and
targeting genomes. Nat Biotechnol. 2014;32(4):347–55.
4. Thyme SB, Akhmetova L, Montague TG, Valen E, Schier AF. Internal guide
RNA interactions interfere with Cas9-mediated cleavage. Nat Commun.
2016;7:11750.
5. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF,
Smith I, Tothova Z, Wilen C, Orchard R, et al. Optimized sgRNA design to
maximize activity and minimize off-target effects of CRISPR-Cas9. Nat
Biotechnol. 2016;34(2):184–91.
6. Ledford H. CRISPR, the disruptor. Nature. 2015;522:20–4.
7. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and
challenges. Nat Med. 2015;21(2):121–31.
8. Tycko J, Myer VE, Hsu PD. Methods for Optimizing CRISPR-Cas9 Genome
Editing Specificity. Mol Cell. 2016;63(3):355–70.
9. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A
programmable dual-RNA-guided DNA endonuclease in adaptive bacterial
immunity. Science. 2012;337(6096):816–21.
10. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W,
Marraffini LA, et al. Multiplex genome engineering using CRISPR/Cas
systems. Science. 2013;339(6121):819–23.
11. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-
frequency off-target mutagenesis induced by CRISPR-Cas nucleases in
human cells. Nat Biotechnol. 2013;31(9):822–6.
12. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y,
Fine EJ, Wu X, Shalem O, et al. DNA targeting specificity of RNA-guided
Cas9 nucleases. Nat Biotechnol. 2013;31(9):827–32.
13. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim JS. Analysis of off-target
effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.
Genome Res. 2014;24(1):132–41.
14. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. High-throughput
profiling of off-target DNA cleavage reveals RNA-programmed Cas9
nuclease specificity. Nat Biotechnol. 2013;31(9):839–43.
15. Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N, Wile BM,
Vertino PM, Stewart FJ, Bao G. CRISPR/Cas9 systems have off-target activity
with insertions or deletions between target DNA and guide RNA sequences.
Nucleic Acids Res. 2014;42(11):7473–85.
16. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L,
Church GM. CAS9 transcriptional activators for target specificity screening
and paired nickases for cooperative genome engineering. Nat Biotechnol.
2013;31(9):833–8.
17. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, Cheng AW, Trevino
AE, Konermann S, Chen S, et al. Genome-wide binding of the CRISPR
endonuclease Cas9 in mammalian cells. Nat Biotechnol. 2014;32(7):670–6.
18. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M. Genome-wide analysis reveals
characteristics of off-target sites bound by the Cas9 endonuclease. Nat
Biotechnol. 2014;32(7):677–83.
19. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V,
Wyvekens N, Khayter C, Iafrate AJ, Le LP, et al. GUIDE-seq enables
genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.
Nat Biotechnol. 2015;33(2):187–97.
20. Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim J-I, Kim J-S.
Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in
human cells. Nat Methods. 2015;12(3):237–43.
21. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B,
Shalem O, Wu X, Makarova KS, et al. In vivo genome editing using
Staphylococcus aureus Cas9. Nature. 2015;520(7546):186–91.
22. Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, Wang L, Hodgkins A,
Iyer V, Huang X, et al. Efficient genome modification by CRISPR-Cas9 nickase
with minimal off-target effects. Nat Methods. 2014;11(4):399–402.
23. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, Goodwin MJ,
Aryee MJ, Joung JK. Dimeric CRISPR RNA-guided FokI nucleases for highly
specific genome editing. Nat Biotechnol. 2014;32(6):569–76.
Zhu et al. BMC Genomics  (2017) 18:379 Page 9 of 10
24. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to
FokI nuclease improves the specificity of genome modification. Nat
Biotechnol. 2014;32(6):577–82.
25. Bolukbasi MF, Gupta A, Oikemus S, Derr AG, Garber M, Brodsky MH, Zhu LJ,
Wolfe SA. DNA-binding-domain fusions enhance the targeting range and
precision of Cas9. Nat Methods. 2015;12(12):1150–6.
26. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally
engineered Cas9 nucleases with improved specificity. Science (New York,
NY). 2016;351(6268):84–8.
27. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung
JK. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide
off-target effects. Nature. 2016;529(7587):490–5.
28. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales
APW, Li Z, Peterson RT, Yeh J-RJ, et al. Engineered CRISPR-Cas9 nucleases
with altered PAM specificities. Nature. 2015;523(7561):481–5.
29. Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z, Joung JK.
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by
modifying PAM recognition. Nat Biotechnol. 2015;33(12):1293–8.
30. Lee CM, Cradick TJ, Bao G. The Neisseria meningitidis CRISPR-Cas9
System Enables Specific Genome Editing in Mammalian Cells. Mol
Ther. 2016;24(3):645–54.
31. Kim D, Kim J, Hur JK, Been KW, Yoon SH, Kim JS. Genome-wide analysis
reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol.
2016;34(8):863–8.
32. Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw
ZR, Aryee MJ, Joung JK. Genome-wide specificities of CRISPR-Cas Cpf1
nucleases in human cells. Nat. Biotechnol. 2016;34:869–74.
33. Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW. Genome-wide detection of
DNA double-stranded breaks induced by engineered nucleases. Nat
Biotechnol. 2015;33(2):179–86.
34. Lupiáñez DG, Kraft K, Heinrich V, Krawitz P, Brancati F, Klopocki E, Horn D,
Kayserili H, Opitz JM, Laxova R, et al. Disruptions of topological chromatin
domains cause pathogenic rewiring of gene-enhancer interactions. Cell.
2015;161(5):1012–25.
35. Torres R, Martin MC, Garcia A, Cigudosa JC, Ramirez JC, Rodriguez-Perales S.
Engineering human tumour-associated chromosomal translocations with
the RNA-guided CRISPR-Cas9 system. Nat Commun. 2014;5:3964.
36. Choi PS, Meyerson M. Targeted genomic rearrangements using CRISPR/Cas
technology. Nat Commun. 2014;5:3728.
37. Ghezraoui H, Piganeau M, Renouf B, Renaud J-B, Sallmyr A, Ruis B, Oh S,
Tomkinson AE, Hendrickson EA, Giovannangeli C, et al. Chromosomal
translocations in human cells are generated by canonical nonhomologous
end-joining. Mol Cell. 2014;55(6):829–42.
38. Wang X, Wang Y, Wu X, Wang J, Wang Y, Qiu Z, Chang T, Huang H,
Lin R-J, Yee J-K. Unbiased detection of off-target cleavage by CRISPR-
Cas9 and TALENs using integrase-defective lentiviral vectors. Nat
Biotechnol. 2015;33(2):175–8.
39. Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S,
Bizhanova A, et al. Therapeutic genome editing by combined viral and non-
viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;
34(3):328–33.
40. Tsai SQ, Topkar VV, Joung JK, Aryee MJ. Open-source guideseq software for
analysis of GUIDE-seq data. Nat Biotechnol. 2016;34(5):483.
41. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson
JA. Efficient genome engineering in human pluripotent stem cells using
Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013;110(39):
15644–9.
42. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS,
Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, et al. Cpf1 Is a
Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell. 2015;
163(3):759-71. doi:10.1016/j.cell.2015.09.038.
43. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J
Comput Graph Stat. 1996;5:299–314.
44. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development
for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
45. Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R,
Morgan MT, Carey VJ. Software for computing and annotating genomic
ranges. PLoS Comput Biol. 2013;9(8):e1003118.
46. Zhu LJ, Gazin C, Lawson ND, Pagès H, Lin SM, Lapointe DS, Green MR.
ChIPpeakAnno: a bioconductor package to annotate ChIP-seq and ChIP-
chip data. BMC Bioinf. 2010;11(1):237.
47. Zhu LJ. Integrative analysis of ChIP-chip and ChIP-seq dataset. Methods Mol
Biol. 2013;1067:105–24.
48. Zhu LJ, Holmes BR, Aronin N, Brodsky MH. CRISPRseek: a bioconductor
package to identify target-specific guide RNAs for CRISPR-Cas9 genome-
editing systems. PLoS ONE. 2014;9(9):e108424.
49. Zhu LJ. Overview of guide RNA design tools for CRISPR-Cas9 genome
editing technology. Frontiers in Biology. 2015;10(4):289–96. http://link.
springer.com/article/10.1007%2Fs11515-015-1366-y.
50. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma
powers differential expression analyses for RNA-sequencing and microarray
studies. Nucleic Acids Res. 2015;43(7):e47.
51 Zetsche B, Volz SE, Zhang F. A split-Cas9 architecture for inducible genome
editing and transcription modulation. Nat Biotechnol. 2015;33(2):139–42.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhu et al. BMC Genomics  (2017) 18:379 Page 10 of 10
